Clinical Trial Detail

NCT ID NCT02900651
Title Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

nasopharynx carcinoma

sarcoma

prostate cancer

Advanced Solid Tumor

diffuse large B-cell lymphoma

ovarian clear cell carcinoma

stomach cancer

Therapies

MAK683

Age Groups: adult senior

No variant requirements are available.